Abstract
This review focuses on the possibilities for intraoperative processing and isolation of autologous cells, particularly atrial appendage-derived cells (AADCs) and cellular micrografts, and their straightforward use in cell transplantation for heart failure therapy. We review the potential of autologous tissues to serve as sources for cell therapy and consider especially those tissues that are used in surgery but from which the excess is currently discarded as surgical waste. We compare the inculture expanded cells to the freshly isolated ones in terms of evidence-based cost-efficacy and their usability as gene- and RNA therapy vehicles. We also review how financial and authority-based decisions and restrictions sculpt the landscape for patients to participate in academic-based trials. Finally, we provide an insight example into AADCs isolation and processing for epicardial therapy during coronary artery bypass surgery.
Keywords: Autologous cell transplantation, Gene therapy, RNA therapy, Minimal cell manipulation, Cardiac micrografts.
Current Gene Therapy
Title:Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Volume: 16 Issue: 1
Author(s): Milla Lampinen, Antti Vento, Jari Laurikka, Johanna Nystedt, Eero Mervaala, Ari Harjula and Esko Kankuri
Affiliation:
Keywords: Autologous cell transplantation, Gene therapy, RNA therapy, Minimal cell manipulation, Cardiac micrografts.
Abstract: This review focuses on the possibilities for intraoperative processing and isolation of autologous cells, particularly atrial appendage-derived cells (AADCs) and cellular micrografts, and their straightforward use in cell transplantation for heart failure therapy. We review the potential of autologous tissues to serve as sources for cell therapy and consider especially those tissues that are used in surgery but from which the excess is currently discarded as surgical waste. We compare the inculture expanded cells to the freshly isolated ones in terms of evidence-based cost-efficacy and their usability as gene- and RNA therapy vehicles. We also review how financial and authority-based decisions and restrictions sculpt the landscape for patients to participate in academic-based trials. Finally, we provide an insight example into AADCs isolation and processing for epicardial therapy during coronary artery bypass surgery.
Export Options
About this article
Cite this article as:
Lampinen Milla, Vento Antti, Laurikka Jari, Nystedt Johanna, Mervaala Eero, Harjula Ari and Kankuri Esko, Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies, Current Gene Therapy 2016; 16 (1) . https://dx.doi.org/10.2174/1566523216666160104141809
DOI https://dx.doi.org/10.2174/1566523216666160104141809 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Common Unfavourable Genetic Variants in Cerebrovascular Diseases: Recommendation for Supportive Genetic Examinations and Methodological Approaches for Common Genetic Variants
Current Medicinal Chemistry Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets Optimal Management of Hypertension in patients with Ischemic Heart Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Induction of Thyroid Neoplasm Following Plant Medicine Marine Algae (Sargassum): A Rare Case and Review of the Literature
Current Pharmaceutical Biotechnology Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Ranolazine : Effects on Ischemic Heart
Recent Patents on Cardiovascular Drug Discovery HSP70 Family in the Renal Inflammatory Response
Inflammation & Allergy - Drug Targets (Discontinued) The Use of Statins in Respiratory Diseases
Current Respiratory Medicine Reviews Infective Endocarditis Complicating Hypertrophic Obstructive Cardiomyopathy: Is Antibiotic Prophylaxis Really Unnecessary?
Current Cardiology Reviews Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Current Pharmaceutical Design A New Molecular Target of Insulin Action: Regulating the Pivotal PDK1
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving
Current Vascular Pharmacology The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Medication Conveyance Through Nose: Factors Affecting and Novel Applications
Drug Delivery Letters Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Inverse Regulation of MMP-9 and MMP-2 in Long-Term Follow-up After Acute Coronary Syndrome: Lack of Correlation with Platelet and Endothelial Cell Activation Markers
Vascular Disease Prevention (Discontinued) Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews